Constitutional court Directs EsSalud to Evaluate Coverage for Duchenne Muscular Dystrophy Treatment
Lima,Peru – October 5,2025 – Peru’s Constitutional Court (TC) has mandated EsSalud,teh nation’s social health insurance provider,to issue a formal opinion regarding the provision of medicines for patients diagnosed with Duchenne muscular dystrophy. The ruling, stemming from case Exp.-01062-2024-PA-TC-LP, compels EsSalud to assess the feasibility of covering treatments for this progressive and debilitating genetic disorder.
This decision arrives as a critical juncture for peruvian families grappling with Duchenne muscular dystrophy, a condition primarily affecting males, causing progressive muscle weakness and ultimately leading to respiratory and cardiac complications. The TC’s order seeks to clarify the extent of EsSalud’s responsibility in ensuring access to necessary medications, perhaps impacting the quality of life and longevity of individuals living with this rare disease.The court’s full decision is available for review here.
The TC’s directive requires EsSalud to provide a complete evaluation of the available therapeutic options, their efficacy, and associated costs. This assessment will inform future policy decisions regarding the inclusion of these medications within EsSalud’s benefits package. Interested parties can sign up for a course on planning for the notary function starting October 21st via WhatsApp at +51921492114, or request further information about a course including two free books and a payment plan until October 15th at +51920528917.
